I期临床试验-话题@MedSci

#I期临床试验#

226篇内容 | 3897人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2088709, encodeId=f3dc2088e09ad, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=NEJM：免疫治疗在晚期三阴乳腺癌III期临床试验中成功！中位总生存期提高61.3%, objectType=article, longId=151769, objectId=5ffc151e69a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ffc151e69a2, replyNumber=0, likeNumber=68, createdTime=2018-11-27, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ffc151e69a2, moduleTitle=NEJM：免疫治疗在晚期三阴乳腺癌III期临床试验中成功！中位总生存期提高61.3%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ffc151e69a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088701, encodeId=b4bb2088e01f3, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Teva的皮下哮喘药物在III期临床试验中失败, objectType=article, longId=127488, objectId=74dd12e488a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74dd12e488a0, replyNumber=0, likeNumber=109, createdTime=2018-08-26, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74dd12e488a0, moduleTitle=Teva的皮下哮喘药物在III期临床试验中失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74dd12e488a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088699, encodeId=72a1208869950, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=EUR J Cancer：聚乙二醇化脂质体多柔比星联合trebananib或安慰剂治疗卵巢癌的随机双盲III期临床试验, objectType=article, longId=125219, objectId=0ec912521937, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ec912521937, replyNumber=0, likeNumber=53, createdTime=2018-09-11, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ec912521937, moduleTitle=EUR J Cancer：聚乙二醇化脂质体多柔比星联合trebananib或安慰剂治疗卵巢癌的随机双盲III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ec912521937)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088692, encodeId=411f208869203, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=诺华ACZ885在III期临床试验CANTOS受试者亚组中降低心血管风险25%, objectType=article, longId=120485, objectId=e3de120485e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3de120485e7, replyNumber=0, likeNumber=78, createdTime=2018-04-25, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3de120485e7, moduleTitle=诺华ACZ885在III期临床试验CANTOS受试者亚组中降低心血管风险25%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3de120485e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088700, encodeId=60b22088e003b, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=JAMA：idalopirdine治疗轻中度阿尔斯海默III期临床试验失败, objectType=article, longId=126123, objectId=8fa3126123fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fa3126123fa, replyNumber=0, likeNumber=42, createdTime=2018-01-30, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fa3126123fa, moduleTitle=JAMA：idalopirdine治疗轻中度阿尔斯海默III期临床试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fa3126123fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088695, encodeId=1db5208869514, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=EUR J Cancer：放疗联合卡培他滨和索拉非尼治疗晚期KRAS突变的直肠癌：I / II期临床试验（SAKK 41/08）, objectType=article, longId=124481, objectId=c81c12448125, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c81c12448125, replyNumber=0, likeNumber=52, createdTime=2018-06-13, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c81c12448125, moduleTitle=EUR J Cancer：放疗联合卡培他滨和索拉非尼治疗晚期KRAS突变的直肠癌：I / II期临床试验（SAKK 41/08）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c81c12448125)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088696, encodeId=a1df2088696d3, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=EUR J Cancer：veliparib治疗BRCA突变的胰腺导管腺癌的II期临床试验, objectType=article, longId=124749, objectId=622e124e49ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=622e124e49ed, replyNumber=0, likeNumber=77, createdTime=2018-11-20, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=622e124e49ed, moduleTitle=EUR J Cancer：veliparib治疗BRCA突变的胰腺导管腺癌的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=622e124e49ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088693, encodeId=bf9f20886930d, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=EUR J CANCER：多西紫杉醇 vs多西紫杉醇联合卡铂治疗去势难治性前列腺癌的随机II期临床试验：RECARDO试验, objectType=article, longId=124106, objectId=bed9124106d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bed9124106d6, replyNumber=0, likeNumber=69, createdTime=2018-03-31, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bed9124106d6, moduleTitle=EUR J CANCER：多西紫杉醇 vs多西紫杉醇联合卡铂治疗去势难治性前列腺癌的随机II期临床试验：RECARDO试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bed9124106d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088691, encodeId=50f3208869107, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=CLIN CANCER RES：Trebananib用于治疗儿童复发实体肿瘤及原发神经系统肿瘤的Ⅰ期临床试验结果, objectType=article, longId=118031, objectId=498d118031bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=498d118031bc, replyNumber=0, likeNumber=90, createdTime=2017-12-19, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=498d118031bc, moduleTitle=CLIN CANCER RES：Trebananib用于治疗儿童复发实体肿瘤及原发神经系统肿瘤的Ⅰ期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=498d118031bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088689, encodeId=c2302088689e4, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=CLIN CANCER RES：ABC294640治疗晚期实体肿瘤患者的Ⅰ期临床试验结果, objectType=article, longId=110765, objectId=c218110e6568, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c218110e6568, replyNumber=0, likeNumber=59, createdTime=2018-07-12, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c218110e6568, moduleTitle=CLIN CANCER RES：ABC294640治疗晚期实体肿瘤患者的Ⅰ期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c218110e6568)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088687, encodeId=9c2f208868eed, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Chest：西罗莫司和淋巴管肌瘤病中的自噬抑制：I期临床试验结果, objectType=article, longId=101487, objectId=0ee810148e65, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ee810148e65, replyNumber=0, likeNumber=102, createdTime=2018-04-18, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ee810148e65, moduleTitle=Chest：西罗莫司和淋巴管肌瘤病中的自噬抑制：I期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ee810148e65)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088698, encodeId=f4e5208869800, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=EUR J Cancer：化疗联合塞来昔布或曲妥珠单抗治疗乳腺癌患者的多中心随机II期临床试验, objectType=article, longId=125185, objectId=de17125185b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de17125185b2, replyNumber=0, likeNumber=46, createdTime=2018-10-25, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de17125185b2, moduleTitle=EUR J Cancer：化疗联合塞来昔布或曲妥珠单抗治疗乳腺癌患者的多中心随机II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de17125185b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088685, encodeId=e88d2088685da, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=JCO：Pyrotinib治疗HER2阳性转移性乳腺癌Ⅰ期临床试验结果, objectType=article, longId=99073, objectId=0118990e3ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0118990e3ca, replyNumber=0, likeNumber=55, createdTime=2017-09-12, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0118990e3ca, moduleTitle=JCO：Pyrotinib治疗HER2阳性转移性乳腺癌Ⅰ期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0118990e3ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088702, encodeId=2e212088e02cd, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Mithra宣布Donesta的II期临床试验已经完成, objectType=article, longId=128113, objectId=70ca12811316, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70ca12811316, replyNumber=0, likeNumber=81, createdTime=2018-02-26, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70ca12811316, moduleTitle=Mithra宣布Donesta的II期临床试验已经完成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70ca12811316)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088684, encodeId=a6562088684df, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=CHEST：西罗莫司和自噬抑制对LAM治疗效果的I期临床试验, objectType=article, longId=89044, objectId=75b08904459, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75b08904459, replyNumber=0, likeNumber=64, createdTime=2017-11-14, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75b08904459, moduleTitle=CHEST：西罗莫司和自噬抑制对LAM治疗效果的I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75b08904459)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088688, encodeId=7f8a208868887, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Blood: selinexor治疗急性骨髓性白血病的I期临床试验, objectType=article, longId=102914, objectId=1daa10291491, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1daa10291491, replyNumber=0, likeNumber=66, createdTime=2018-01-28, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1daa10291491, moduleTitle=Blood: selinexor治疗急性骨髓性白血病的I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1daa10291491)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088690, encodeId=abd3208869036, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=CLIN CANCER RES：TAK-117治疗晚期恶性肿瘤Ⅰ期临床试验结果, objectType=article, longId=112044, objectId=bb781120446e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb781120446e, replyNumber=0, likeNumber=113, createdTime=2018-06-17, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb781120446e, moduleTitle=CLIN CANCER RES：TAK-117治疗晚期恶性肿瘤Ⅰ期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb781120446e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088686, encodeId=0aeb20886863a, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=ASCO2017：尤文肉瘤靶向新药物TK216 I期临床试验开展, objectType=article, longId=101269, objectId=286810126909, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=286810126909, replyNumber=0, likeNumber=76, createdTime=2017-10-14, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=286810126909, moduleTitle=ASCO2017：尤文肉瘤靶向新药物TK216 I期临床试验开展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=286810126909)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088683, encodeId=7c95208868374, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=辉瑞赫赛汀生物仿制药达乳腺癌III期临床试验主要终点, objectType=article, longId=85558, objectId=25048555835, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25048555835, replyNumber=0, likeNumber=61, createdTime=2017-03-30, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25048555835, moduleTitle=辉瑞赫赛汀生物仿制药达乳腺癌III期临床试验主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25048555835)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088677, encodeId=52fc20886e7c6, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=招募患者：MSC2156119J对比索拉非尼治疗晚期肝细胞癌受试者的有效性、安全性和PK的多中心、随机、Ib联合II期临床试验, objectType=article, longId=56011, objectId=342c560114a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=342c560114a, replyNumber=0, likeNumber=68, createdTime=2016-01-20, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=342c560114a, moduleTitle=招募患者：MSC2156119J对比索拉非尼治疗晚期肝细胞癌受试者的有效性、安全性和PK的多中心、随机、Ib联合II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=342c560114a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床试验

2020-05-29

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

NEJM：免疫治疗在晚期三阴乳腺癌III期临床试验中成功！中位总生存期提高61.3%

2018-11-27

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Teva的皮下哮喘药物在III期临床试验中失败

2018-08-26

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

EUR J Cancer：聚乙二醇化脂质体多柔比星联合trebananib或安慰剂治疗卵巢癌的随机双盲III期临床试验

2018-09-11

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

诺华ACZ885在III期临床试验CANTOS受试者亚组中降低心血管风险25%

2018-04-25

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

JAMA：idalopirdine治疗轻中度阿尔斯海默III期临床试验失败

2018-01-30

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

EUR J Cancer：放疗联合卡培他滨和索拉非尼治疗晚期KRAS突变的直肠癌：I / II期临床试验（SAKK 41/08）

2018-06-13

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

EUR J Cancer：veliparib治疗BRCA突变的胰腺导管腺癌的II期临床试验

2018-11-20

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

EUR J CANCER：多西紫杉醇 vs多西紫杉醇联合卡铂治疗去势难治性前列腺癌的随机II期临床试验：RECARDO试验

2018-03-31

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

CLIN CANCER RES：Trebananib用于治疗儿童复发实体肿瘤及原发神经系统肿瘤的Ⅰ期临床试验结果

2017-12-19

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

CLIN CANCER RES：ABC294640治疗晚期实体肿瘤患者的Ⅰ期临床试验结果

2018-07-12

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Chest：西罗莫司和淋巴管肌瘤病中的自噬抑制：I期临床试验结果

2018-04-18

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

EUR J Cancer：化疗联合塞来昔布或曲妥珠单抗治疗乳腺癌患者的多中心随机II期临床试验

2018-10-25

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

JCO：Pyrotinib治疗HER2阳性转移性乳腺癌Ⅰ期临床试验结果

2017-09-12

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Mithra宣布Donesta的II期临床试验已经完成

2018-02-26

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

CHEST：西罗莫司和自噬抑制对LAM治疗效果的I期临床试验

2017-11-14

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Blood: selinexor治疗急性骨髓性白血病的I期临床试验

2018-01-28

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

CLIN CANCER RES：TAK-117治疗晚期恶性肿瘤Ⅰ期临床试验结果

2018-06-17

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

ASCO2017：尤文肉瘤靶向新药物TK216 I期临床试验开展

2017-10-14

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

辉瑞赫赛汀生物仿制药达乳腺癌III期临床试验主要终点

2017-03-30

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

招募患者：MSC2156119J对比索拉非尼治疗晚期肝细胞癌受试者的有效性、安全性和PK的多中心、随机、Ib联合II期临床试验

2016-01-20

科室
- - 订阅+
  - 更多科室
工具
服务